pazopanib
pazopanib: sourced relationships with 1 company · 9 clinical trials tracked · 1 FDA decision.
pazopanib evidence translation
What we can confirm
1 FDA record · 9 tracked trials
What it means
What to watch
Prepared research question
How could pazopanib → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 2 study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Novartis AG (NVS) Reported 2009-10-19 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (9)
A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Primary endpoint: Progression-free Survival (PFS)
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas
Primary endpoint: Determination of the safety and technical feasibility of microdevice insertion/removal, as assessed by adverse events by CTCAE 5.0.
A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)
Primary endpoint: Overall Survival (OS)
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Primary endpoint: Event-free survival (EFS)
A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)
Primary endpoint: for dose escalation part: the Maximum tolerated dose (MTD) of HDM201 given in combination with a fixed dose of pazopanib.
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
Primary endpoint: Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC)
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Primary endpoint: Number of Participants With TEAEs and SAEs Observed During the Study of Pegilodecakin
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria
Primary endpoint: Dose limiting toxicity (DLT) incidence (according DLT definition) during the first treatment cycle with pazopanib (28 days)
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
Primary endpoint: Time to Overall Treatment Failure
Frequently asked questions
Which companies have sourced relationships with pazopanib?
pazopanib has dated SEC/FDA relationship records for Novartis AG.
How many clinical trials involve pazopanib?
BioSniper tracks 9 clinical trials involving pazopanib.
What is pazopanib's latest FDA decision?
The most recent tracked FDA decision for pazopanib is Approval, dated October 19, 2009.